Melanotan 2: The Tanning and Libido Peptide, Examined
A clear-eyed look at Melanotan 2: real but dated proof-of-concept evidence for tanning and erections, set against a thin safety record dominated by harm reports.
By Research Rats Editorial TeamReviewed by Research Rats Editorial Team
Evidence profile
Assessed 2026-07-02A non-selective melanocortin agonist with genuine but small and dated human proof-of-concept data; the molecule was never approved (its analogues were), long-term safety is unstudied, and the recent literature is dominated by harm reports.
Well-supported non-selective melanocortin-receptor agonism (MC1R tanning; central MC4R/MC3R sexual and appetite effects).
Limited preclinical work, including rat studies mapping central and peripheral sexual pathways.
Small, dated crossover RCTs (n=10-20, mostly single-dose) in erectile dysfunction showed the claimed effects; these are proof-of-concept, not a safety dossier.
The effects are real but demonstrated only in small proof-of-concept studies; the molecule itself was never taken forward.
Long-term safety is essentially unstudied; the recent literature is dominated by harm reports, forensic seizures and studies of an unregulated user community.
The idea was taken forward as approved analogues (afamelanotide, bremelanotide/PT-141), not as MT-II itself.
Genuine but old and small efficacy data, with thin safety characterisation, keep confidence low.
Unapproved and illegal to sell for human use in the US, UK, EU and Australia; subject to MHRA public-health warnings, with documented contamination and a melanoma/mole-monitoring concern. FDA Category 2 nomination later withdrawn — not currently in the active Category 2 table, which is not a clearance and leaves the concerns FDA published standing.
Bars show the state of evidence, not desirability. A strong rating on any axis does not mean a compound is safe, effective, or recommended. Human evidence is often limited. Not medical advice.
Overview
Melanotan 2 (MT-II) is one of the more notorious "research peptides" in circulation: an injectable that darkens skin without much sun and, as a side effect, triggers spontaneous erections and dampens appetite. It is best understood as a half-told story. The interesting part — the original science — is genuine but old and small. The part that dominates the recent literature is a string of harm reports, forensic seizures of dodgy product and studies of an unregulated user community.
Here is the honest summary. MT-II works pharmacologically; the early human trials really did show what they claimed [1][2][3]. But MT-II itself was never developed into an approved medicine. Instead, two structurally related compounds went through full clinical development and reached the market: afamelanotide (Scenesse) and bremelanotide (Vyleesi), both approved in 2019 [4][7]. MT-II, by contrast, remains unlicensed, unregulated and illegal to sell for human use, and its long-term safety is essentially unstudied [7][8]. If you take nothing else away: the safety data for the approved cousins does not transfer to the grey-market vial.
What it is & how it works
MT-II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). It was deliberately engineered to be superpotent and resistant to enzymatic breakdown compared with natural alpha-MSH [5]. Crucially, it is a non-selective agonist — it activates the whole melanocortin receptor family (MC1R, MC3R, MC4R and MC5R) rather than picking one. That promiscuity explains why a single compound produces such a scattered set of effects.
- Tanning comes from MC1R agonism on melanocytes, which drives eumelanin synthesis (melanogenesis) and darkens skin with or without UV exposure — the original intended use [5].
- Sexual effects are centrally mediated: agonism at MC4R (and MC3R) in the hypothalamus, particularly the paraventricular nucleus, drives erection and increases sexual desire. This is a brain-level mechanism, fundamentally different from peripheral vasodilators like PDE5 inhibitors. Rat work shows both central (hypothalamic) and peripheral (lumbar sympathetic chain) pathways are recruited [6].
- Appetite suppression and weight loss also flow from MC4R agonism.
- Off-target effects are real. Common trial side effects included nausea and yawning/stretching, and a mouse study showed MT-II can act outside the canonical melanocortin receptors entirely — triggering mast-cell degranulation and histamine release (partly via MRGPRB2), causing hypothermia [14]. That is a useful reminder that "melanocortin agonist" does not fully describe what this molecule does in a body.
What the published research says
The efficacy evidence is genuine but thin and dated — small academic trials from the University of Arizona in the late 1990s and 2000.
- In a double-blind, placebo-controlled crossover trial in men with psychogenic erectile dysfunction (n=10), MT-II at 0.025 mg/kg produced clinically apparent erections in 8 of 10 men, with mean time at over 80% tip rigidity of 38 minutes versus 3 minutes on placebo. Transient nausea, yawning/stretching and reduced appetite were the main side effects [1].
- A second crossover RCT in men with organic ED (n=10) found MT-II initiated erections in 12 of 19 injections versus 1 of 21 placebo injections, and significantly increased self-reported sexual desire; 4 of 19 MT-II injections caused severe nausea [2].
- Pooled human experience (n=20) reported erection without sexual stimulation in 17 of 20 men, and increased sexual desire after 68% of doses versus 19% for placebo, with severe nausea in roughly 13% at 0.025 mg/kg [3].
Note the scale: these are single-dose studies in 10 to 20 men, decades ago. They are proof-of-concept, not a safety dossier. The originators' own review describes how MT-I (tanning) and MT-II were patented and tested, and how MT-II's promise led to the development of the analogue PT-141 — bremelanotide — for sexual dysfunction [4]. In other words, the pharma industry took the idea forward but not the molecule.
The recent MT-II literature is dominated by harm: a 2017 review links unregulated melanotan to melanocytic changes in moles, new dysplastic naevi and four reports of melanoma during or after use, explicitly contrasting it with the tested analogue afamelanotide [7]. A British Journal of Dermatology review flagged MHRA public-health warnings on blood-borne virus transmission and impurity [8].
Dose & Exposure Context
Dose and Exposure Data
Research Rats reports dose and exposure figures as evidence context, not use instructions. Licensed doses are shown only within their approved medical setting. Trial doses describe study conditions. Community-reported figures are unverified, lower-certainty claims included so members can distinguish evidence from online convention.
Exposure Snapshot
- Regulatory status: Unapproved and illegal to sell for human use in the US, UK, EU and Australia; subject to MHRA public-health warnings on impurity and blood-borne virus transmission. Never developed into a medicine — two structural relatives (afamelanotide, bremelanotide) were, reaching the market in 2019. The FDA lists Melanotan II among bulk substances nominated to its Category 2 compounding list — substances identified as potentially presenting significant safety risks — with the nomination later withdrawn, so it is not currently in the active Category 2 table. That withdrawal is not an approval, a clearance, or a finding that the concerns were resolved — the FDA continues to publish them: possible immunogenicity for certain routes from aggregation or peptide-related impurities, and published case reports of serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism. Melanotan I is a different substance and is not on either FDA table [15].
- Strongest available exposure source: Small, dated, supervised academic crossover studies in men with erectile dysfunction (late 1990s–2000).
- Regulated dose information: Not available.
- Human exposure evidence: Limited — proof-of-concept only; single-dose studies in groups of ten to twenty men.
- Preclinical exposure evidence: Limited — rat erectile-pathway mapping and a mouse off-target mast-cell signal.
- Community discussion: Present and substantial — tanning, spontaneous erections and appetite suppression, but dominated by harm reports and supply problems.
- Research Rats confidence: Low — a genuine but tiny and dated efficacy signal set against a growing, poorly-bounded harm record.
- Principal uncertainty: The long-term safety of MT-II itself is essentially unstudied, and the approved cousins' safety record does not transfer.
Members only
Detailed exposure data is available to members
Research Rats reports dose and exposure figures as evidence context, not use instructions. The detailed section sets out what quantities were licensed, studied, or reported, each tied to its source:
- Regulated Prescribing Context
- Human Clinical Exposure
- Preclinical Exposure
- Community-Reported Exposure Patterns
- Interpretation
Regulatory status, evidence strength and safety context above remain public.
Community Context
Community discussion shows how a compound is talked about and used outside formal research. Research Rats tracks recurring claimed benefits, adverse experiences, disagreements and product-quality concerns, then compares them with the available evidence. These reports are uncontrolled and often impossible to verify, so they are treated as signals rather than findings. Their value is in showing what deserves scrutiny, not in proving what works or providing instructions.
Community-Reported Exposure Patterns
Community discussion is dominated by deep tanning with minimal sun, spontaneous erections and increased libido, and reduced appetite. Unusually, the direction of these claims matches the small human studies — but matching direction is not matching evidence: those studies were tiny, decades old, single-dose and supervised, whereas community practice is repeated, unsupervised and uses material of unknown identity. Reports describe nausea, flushing, yawning and stretching, mole darkening and prolonged erections, often traded on forums alongside sunbed use and without telling a clinician. As unverified signals they cannot establish safety, efficacy or prevalence.
Recurring claimed benefits Recurring themes are a deep tan with minimal sun exposure, spontaneous erections and increased libido, and reduced appetite. Unusually for this field, the direction of these claims does match the direction of the small human studies [1][2][3]. That correspondence is easy to over-read: matching direction is not matching evidence. The studies were single-administration, tiny, decades old, and conducted under supervision; the community practice is repeated, unsupervised, and uses material of unknown identity. These remain claims and signals, not demonstrated outcomes.
Recurring reported adverse experiences Self-reports commonly describe nausea, facial flushing, yawning and stretching, darkening of moles and freckles, and unwanted or prolonged erections. A qualitative study of online discussion forums found users trading exactly these experiences, frequently alongside sunbed use and frequently without telling a clinician [12]. Nausea and yawning/stretching were also among the common effects in the original trials [1][2]. As self-reports these are possible signals, not incidence rates — no denominator, no confirmed diagnosis, no follow-up.
Expert commentary context The published clinical and dermatological literature is unusually direct here. A review of unregulated alpha-MSH analogue use links melanotan to melanocytic change, new dysplastic naevi and reports of melanoma during or after use, and explicitly contrasts it with the tested analogue afamelanotide [7]. A British Journal of Dermatology review flagged MHRA public-health warnings on impurity and blood-borne virus transmission [8]. Priapism is documented as a urological emergency in a case report where erectile function had not recovered at follow-up [11]. Expert commentary contextualises the community narrative; it does not validate it.
Context and confounders Community reports are confounded in ways that bear directly on the two headline claims. Tanning is routinely pursued alongside sunbed or sun exposure, which darkens skin independently. Sexual-function reports are self-assessed, unblinded, and strongly susceptible to expectation. Product identity, purity and dose accuracy are unknown; there is no monitoring; and survivorship, selection and reporting bias operate throughout, including deleted or edited posts. The harm literature is drawn from case reports and clinical presentations, which capture severe events while leaving the denominator unknown.
Supply and product-quality concerns Supply is not a peripheral concern here; it is central. MT-II is illegal to sell for human use and is unregulated, with documented contamination, mislabelling, incorrect concentration and counterfeits — forensic mass-spectrometry work has confirmed MT-II and bremelanotide in police-seized samples circulating alongside steroids [13]. Injecting unregulated material, and sharing needles, carries blood-borne virus risk under an explicit MHRA warning [8]. Research Rats does not reproduce administration patterns or sourcing detail.
Evidence interpretation The asymmetry is the point. Community claims track a real pharmacological effect, which is precisely what makes them persuasive — and that effect was demonstrated in small groups of men, in single-administration studies, in the late 1990s and 2000. The harm record, by contrast, keeps growing: renal infarction, rhabdomyolysis, priapism, contaminated product, and a mole-and-melanoma signal that also complicates skin-cancer detection, because users often do not disclose use [7][9][10][11][12][13]. Community reports cannot establish causality, incidence, dose-response or long-term risk. They do show, clearly, that an unstudied practice has outrun a small and dated evidence base.
Safety & considerations
This is where MT-II earns its caution. The compound is unapproved and illegal to sell for human use in the US, UK, EU and Australia. Product is unregulated, with documented contamination, mislabelling, incorrect concentration and counterfeits — forensic analysis has confirmed MT-II and bremelanotide in police-seized samples sold alongside steroids [13].
The central concern is dermatological. Case reports link MT-II to darkening and change in existing moles, new and dysplastic naevi, and at least four reports of melanoma arising during or after use [7]. Causality is not proven, but the real danger is twofold: it may mask or mimic malignant change, and it complicates skin-cancer detection — made worse by the common practice of co-using sunbeds and not telling a doctor [8][12].
Documented serious systemic events include:
- Rhabdomyolysis with acute kidney injury and sympathomimetic toxicity — one mass-spectrometry-confirmed case after a 6 mg injection had CPK peaking near 17,773 IU/L [10].
- Renal infarction, with proposed thrombotic and direct renal-toxic mechanisms [9].
- Priapism — a prolonged, painful erection that is a urological emergency. One case required cavernosal aspiration, irrigation and phenylephrine, and erectile function had not recovered at four-week follow-up [11].
- Endocrine and metabolic disturbance, plus the off-target mast-cell/histamine activation seen in animals [14].
Safety note
MT-II is unlicensed and unregulated. You cannot know what is in the vial, at what concentration, or whether it is sterile. Injecting and sharing needles carries blood-borne virus risk (an explicit MHRA warning) [8]. Priapism lasting more than four hours and any rapidly changing, darkening or newly atypical mole are medical emergencies — seek urgent care and disclose MT-II use, however awkward. Long-term safety of MT-II itself is essentially unknown: the original trials were single-dose and tiny. And do not assume the safety record of the approved analogues afamelanotide or bremelanotide applies here — it does not [7].
The bottom line
Melanotan 2 is a pharmacologically real compound with a genuine, if dated, evidence base: small but credible trials show it darkens skin and reliably produces erections and increased sexual desire in men, via brain-level melanocortin signalling [1][2][3][6]. That story is interesting enough that two relatives became approved medicines [4].
But MT-II itself stayed behind in the grey market. The modern literature on it is not a record of benefit refined over time — it is a record of harm: rhabdomyolysis, renal infarction, priapism, contaminated product and a worrying signal around moles and melanoma [7][9][10][11][13]. For an informed self-experimenter, the asymmetry is the whole point. The upside is well characterised and modest in scope; the downside is poorly bounded, unregulated and occasionally severe. If skin health, sexual function or appetite are the goal, the regulated, tested options — and a frank conversation with a clinician — sit on far firmer ground than an unlabelled vial.
References
- [1]Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N (1998). Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study The Journal of Urology. PMID 9679884
- [2]Wessells H, Gralnek D, Dorr R, Hruby VJ, Hadley ME, Levine N (2000). Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction Urology. DOI 10.1016/s0090-4295(00)00680-4
- [3]Wessells H, Levine N, Hadley ME, Dorr R, Hruby V (2000). Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II International Journal of Impotence Research. DOI 10.1038/sj.ijir.3900582
- [4]Hadley ME, Dorr RT (2006). Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization Peptides. DOI 10.1016/j.peptides.2005.01.029
- [5]Hadley ME, Hruby VJ, Blanchard J, Dorr RT, Levine N, Dawson BV, al-Obeidi F, Sawyer TK (1998). Discovery and development of novel melanogenic drugs. Melanotan-I and -II Pharmaceutical Biotechnology. DOI 10.1007/0-306-47384-4_25
- [6]Giuliano F, Clement P, Droupy S, Alexandre L, Bernabe J (2005). Melanotan-II: Investigation of the inducer and facilitator effects on penile erection in anaesthetized rat Neuroscience. DOI 10.1016/j.neuroscience.2005.11.008
- [7]Habbema L, Halk AB, Neumann M, Bergman W (2017). Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review International Journal of Dermatology. DOI 10.1111/ijd.13585
- [8]Langan EA, Nie Z, Rhodes LE (2010). Melanotropic peptides: more than just 'Barbie drugs' and 'sun-tan jabs'? British Journal of Dermatology. DOI 10.1111/j.1365-2133.2010.09891.x
- [9]Peters B, Hadimeri H, Wahlberg R, Afghahi H (2020). Melanotan II: a possible cause of renal infarction: review of the literature and case report CEN Case Reports. DOI 10.1007/s13730-020-00447-z
- [10]Nelson ME, Bryant SM, Aks SE (2012). Melanotan II injection resulting in systemic toxicity and rhabdomyolysis Clinical Toxicology. DOI 10.3109/15563650.2012.740637
- [11]Dreyer BA, Amer T, Fraser M (2019). Melanotan-induced priapism: a hard-earned tan BMJ Case Reports. DOI 10.1136/bcr-2018-227644
- [12]Gilhooley E, Daly S, McKenna D (2021). Melanotan II User Experience: A Qualitative Study of Online Discussion Forums Dermatology (Basel). DOI 10.1159/000514492
- [13]Mestria S, Odoardi S, Frison G, Strano Rossi S (2020). LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs Drug Testing and Analysis. DOI 10.1002/dta.2986
- [14]Jain S, Panyutin A, Liu N, et al. (2018). Melanotan II causes hypothermia in mice by activation of mast cells and stimulation of histamine 1 receptors American Journal of Physiology - Endocrinology and Metabolism. DOI 10.1152/ajpendo.00024.2018
- [15]U.S. Food and Drug Administration (2026). Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — Melanotan II listed among nominated-but-withdrawn substances FDA — Human Drug Compounding. FDA category 2 tables; page content current as of 22 April 2026
Disclaimer. For educational and research purposes only. Not medical advice. We do not sell peptides or compounds.
Discussion (0)
General, evidence-based discussion only. Please don't post personal medical details, dosing, sourcing, or anything that identifies you or someone else. By posting you agree to our Acceptable Use rules. Comments are moderated and may be held or removed.
Loading the discussion…
Loading…
[ Related research ]
GHK-Cu (Copper Peptide): What the Evidence Actually Shows
A clear-eyed look at GHK-Cu: strong lab and animal mechanism data, thin human evidence, and why much of the glowing skincare literature comes with a conflict of interest.
Glutathione: What the Evidence Actually Shows for Skin Lightening
Oral glutathione has modest, reversible skin-lightening evidence from small trials; IV use has essentially no proof of benefit and real safety risks.
Melanotan 1 (Afamelanotide): The Approved MC1R Peptide, Honestly Assessed
Afamelanotide is a regulator-approved alpha-MSH analogue with strong evidence for EPP phototoxicity — and is not the grey-market tanning peptide it is often confused with.
SNAP-8 (Acetyl Octapeptide-3): The Evidence Behind the "Needle-Free Botox" Peptide
A clear-eyed look at SNAP-8: a plausible SNARE-targeting cosmetic peptide whose standalone human efficacy data are essentially absent.